Recent Reports

Evidence report on anti-androgen drugs for high risk prostate cancer. This report will serve as the basis for discussion during a public meeting of Midwest CEPAC in September 2018.

View More on this Topic

ICER’s Draft Evidence Report, open to public comment until September 20, 2018. For more information on submitting a public comment, please visit our stakeholder engagement page.

View More on this Topic

ICER’s Draft Evidence Report on treatments for hereditary transthyretin-related amyloidosis, open to public comment until August 17, 2018 at 5pm ET. For more information on submitting a public comment, please visit our stakeholder engagement page.

View More on this Topic



Materials

New England CEPAC

Beta Thalassemia: Open Input Period

ICER

Valuing A Cure Report: Final White Paper and Methods Adaptations

ICER

Valuing a Cure: ICER Responses to Public Comment

New England CEPAC

Diabetes: Response to Public Comments

ICER

Unsupported Price Increase Report

CVD: Final Policy Recommendations

Midwest CEPAC

NASH: Revised Scoping Document

Midwest CEPAC

NASH: Stakeholder List

Midwest CEPAC

NASH: Public Comments on Draft Scoping Document

Midwest CEPAC

NASH: Draft Scoping Document

Pharmaceutical Rebates: Journal Publication

ICER

Model Transparency: Journal Publication